Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing  Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Slides:



Advertisements
Similar presentations
Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.
Advertisements

Das_Figure S1 USP15 USP4 USP11 49% 60% 39 % 71 % 52 % 54 %
Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,
Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy 
Volume 129, Issue 4, Pages (October 2005)
Volume 142, Issue 4, Pages e3 (April 2012)
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression  Dongdong Lu, Chang Han, Tong.
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Roles of the cytoplasmic domains of the α and β subunits of human granulocyte- macrophage colony-stimulating factor receptor  Akihiko Muto, PhDa, Sumiko.
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,
Volume 133, Issue 5, Pages (November 2007)
The Sterile 20-like Kinase Tao-1 Controls Tissue Growth by Regulating the Salvador- Warts-Hippo Pathway  Carole L.C. Poon, Jane I. Lin, Xiaomeng Zhang,
Volume 19, Issue 2, Pages (July 2005)
MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations 
Volume 11, Issue 4, Pages (April 2003)
Volume 138, Issue 3, Pages e2 (March 2010)
Volume 5, Issue 4, Pages (April 2004)
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation 
TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas
Autoinhibition of c-Abl
VAMP2–NRG1 Fusion Gene is a Novel Oncogenic Driver of Non–Small-Cell Lung Adenocarcinoma  Yeonjoo Jung, PhD, Seunghui Yong, BS, Pora Kim, PhD, Hee-Young.
Volume 19, Issue 2, Pages (February 2017)
Sunny Guin, PhD, Yuanbin Ru, PhD, Murry W
Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer  Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.
Volume 142, Issue 3, Pages (March 2012)
Volume 138, Issue 2, Pages (February 2010)
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,
RNF168 Promotes Noncanonical K27 Ubiquitination to Signal DNA Damage
Activated Leukocyte Cell-Adhesion Molecule (ALCAM) Promotes Malignant Phenotypes of Malignant Mesothelioma  Futoshi Ishiguro, MD, Hideki Murakami, MD,
HES1 is a novel interactor of the Fanconi anemia core complex
Yuen Yee Cheng, PhD, Michaela B
Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma  Erick Riquelme, PhD, Milind B. Suraokar,
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
ASK1 Is Essential for JNK/SAPK Activation by TRAF2
Eun-Joo Kim, Jeong-Hoon Kho, Moo-Rim Kang, Soo-Jong Um  Molecular Cell 
Volume 17, Issue 5, Pages (October 2016)
Wenqi Wang, Nan Li, Xu Li, My Kim Tran, Xin Han, Junjie Chen 
Volume 18, Issue 4, Pages (May 2005)
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib  Chien-Hung Gow, MD, PhD, Wei-Yu Liao, MD, PhD, Yi-Nan Liu,
Minchul Kim, Taekhoon Kim, Randy L. Johnson, Dae-Sik Lim  Cell Reports 
Yuming Wang, Jennifer A. Fairley, Stefan G.E. Roberts  Current Biology 
Naoko Kanda, Shinichi Watanabe  Journal of Investigative Dermatology 
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression  Dongdong Lu, Chang Han, Tong.
Mutations in Human ARF Exon 2 Disrupt Its Nucleolar Localization and Impair Its Ability to Block Nuclear Export of MDM2 and p53  Yanping Zhang, Yue Xiong 
Volume 17, Issue 1, Pages (January 2005)
Volume 26, Issue 6, Pages (September 2013)
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Volume 18, Issue 2, Pages (January 2017)
Nrf2 Promotes Keratinocyte Proliferation in Psoriasis through Up-Regulation of Keratin 6, Keratin 16, and Keratin 17  Luting Yang, Xueli Fan, Tingting.
The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration  Y. Rebecca Chin, Alex Toker  Molecular.
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,
Regulation of Wnt Signaling by the Nuclear Pore Complex
Yi Tang, Jianyuan Luo, Wenzhu Zhang, Wei Gu  Molecular Cell 
Roles of the cytoplasmic domains of the α and β subunits of human granulocyte- macrophage colony-stimulating factor receptor  Akihiko Muto, PhDa, Sumiko.
Barbara Marinari, Costanza Ballaro, Maranke I
SOCS1 Links Cytokine Signaling to p53 and Senescence
C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas  Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.
Volume 47, Issue 4, Pages (August 2012)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Yap1 Phosphorylation by c-Abl Is a Critical Step in Selective Activation of Proapoptotic Genes in Response to DNA Damage  Dan Levy, Yaarit Adamovich,
Hua Gao, Yue Sun, Yalan Wu, Bing Luan, Yaya Wang, Bin Qu, Gang Pei 
Volume 5, Issue 6, Pages (December 2013)
Naoko Kanda, Shinichi Watanabe  Journal of Investigative Dermatology 
Volume 48, Issue 6, Pages (December 2012)
Volume 20, Issue 11, Pages (November 2012)
Volume 2, Issue 3, Pages (September 2012)
Volume 41, Issue 4, Pages (February 2011)
Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy 
Volume 31, Issue 5, Pages (September 2008)
Presentation transcript:

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing  Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji Tsuta, MD, PhD, Kumiko Kawasaki, Yuka Nakamura, Tomohiro Sakuma, Hisao Asamura, MD, PhD, Akihiko Gemma, MD, PhD, Tesshi Yamada, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 5, Pages 844-851 (May 2015) DOI: 10.1097/JTO.0000000000000493 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Identification of the LATS1–PSEN1 fusion gene. A, Graphic representation of RNA sequencing and comparative genomic hybridization data for MSTO-211H cells. Chromosome ideograms and copy number variation are shown in the outer and middle layers, respectively. Chromosomal translocation is shown in the central layer. The LATS1–PSEN1 fusion is shown in red, and the SLIT2-AC006052.1 and TRAPPC9-GBA3 fusions are shown in blue. B, Nucleotide and deduced amino acid sequences at the break/fusion point of the LATS1–PSEN1 transcript. C, Schematic representation of the deduced domain structure of wild-type LATS1 and LATS1–PSEN1 proteins. Wild-type LATS1 contains the ubiquitin-associated domain (amino acids 100–141), protein kinase domain [705–1010], and AGC-kinase C-terminal domain [1010–1090]. D, Ideogram showing the chromosomal translocation of LATS1 (chromosomes 6 at q25.1) and PSEN1 (chromosome 14 at q24.3). E, Comparative genomic hybridization analysis of chromosome 6 of MSTO-211H cells. F, Expression level of each exon of the LATS1 and PSEN1 genes determined by counting the number of reads in RNA sequencing. Journal of Thoracic Oncology 2015 10, 844-851DOI: (10.1097/JTO.0000000000000493) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Functional significance of the LATS1–PSEN1 fusion gene. A, HEK293 cells were transfected with pcDNA3.1-LATS1-V5, pcDNA3.1-LATS1–PSEN1-V5, or a relevant empty plasmid. Twenty-four hours later, the expression of wild-type LATS1 and LATS1–PSEN1 proteins was confirmed by immunoprecipitation (IP) with anti-V5 antibody or control IgG and blotting with anti-V5 antibody. The immunoprecipitates were then incubated with glutathione S-transferase-YAP recombinant protein at 30°C for 30 minutes and analyzed by blotting with antiphosphorylated YAP and anti-YAP antibodies. B, MSTO-211H cells were transfected with pcDNA3.1-LATS1, pcDNA3.1-LATS1–PSEN1, or an empty vector (Vector). Twenty four hours later, cell lysates were extracted and blotted with antiphosphorylated YAP (p-YAP), anti-YAP, anti-LATS1, and anti-γ-tubulin (loading control) antibodies. Molecular masses (in kilodaltons) are shown to the right. C, Immunofluorescence microscopy analysis of MSTO-211H cells transfected with pcDNA3.1-LATS1-V5 (LATS1), pcDNA3.1-LATS1–PSEN1-V5 (LATS1–PSEN1), or an empty vector (Vector) with anti-V5 and anti-YAP1 antibodies. Nuclei were stained with TOTO-3 Iodide. Bar, 10 μm. D and E, Colony formation (D) and soft-agar colony formation (E) of MSTO-211H cells transfected with pcDNA3.1-LATS1, pcDNA3.1-LATS1–PSEN1, or an empty vector (Vector) and selected with geneticin (G418) for 14 days. Journal of Thoracic Oncology 2015 10, 844-851DOI: (10.1097/JTO.0000000000000493) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Inactivation of Hippo pathway proteins in malignant mesothelioma (MM) cell lines. Immunoblot analysis of KIBRA; SAV1; RASSF1; Merlin; phosphorylated MST (pMST), MST1, and MST2; phosphorylated LATS1 (pLATS1), LATS1, and LATS2; and phosphorylated yes-associated protein (p-YAP), TAZ, 14-3-3, and γ-tubulin (loading control) protein expression in 19 MM cases and Met-5A cells. Molecular masses (in kilodaltons) are shown on the right. Antibodies used are listed in Supplementary Table 8 (Supplemental Digital Content 1, http://links.lww.com/JTO/A805). Journal of Thoracic Oncology 2015 10, 844-851DOI: (10.1097/JTO.0000000000000493) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Activation of yes-associated protein (YAP) in malignant mesothelioma (MM). A, Representative cases of MM showing positive and negative nuclear immunoreactivities with anti-YAP antibody. Original magnification: ×20. B and C, YAP protein (B) and mRNA (C) expression in H2052 and MSTO-211H cells transfected with two small interfering RNAs (siRNAs) against YAP (YAP1-1 and YAP1-2) and control RNA (Control). mRNA expression data are shown as mean ± standard deviation (SD). D, Growth of H2052 and MSTO-211H cells transfected with siRNAs against YAP (YAP1-1 and YAP1-2) and control RNA (Control). The data are shown as the mean of triplicates ± SD. *p < 0.01 (Student's t test). Journal of Thoracic Oncology 2015 10, 844-851DOI: (10.1097/JTO.0000000000000493) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions